Business
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
BOSTON, May 12, 2026--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2026, and recent corporate highlights.
About this update from Pepgen Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/12ee50525b5c5e73434d52f84258be6f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tmYIq4E29EznceV4kHzHMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/12ee50525b5c5e73434d52f84258be6f","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/oB61OK70DFKQynn2VS5q4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/12ee50525b5c5e73434d52f84258be6f","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/L2jqnGif176YeZvucVEqKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/12ee50525b5c5e73434d52f84258be6f","width":1024,"height":512}},"lazy":false},{"type":"text","content":"– FREEDOM2-DM1 5 mg/kg cohort demonstrated favorable safety, splicing and vHOT data, with the totality of results supporting the potential of the ongoing 10 mg/kg dose cohort –","length":176,"tagName":"p","attribs":{}},{"type":"text","content":"– The FREEDOM2 10 mg/kg cohort is fully enrolled, with data on track for 2H 2026 –","length":82,"tagName":"p","attribs":{}},{"type":"text","content":"– Well-funded with $132.3M of cash as of March 31, 2026, sufficient to fund operations through FREEDOM2 12.5 mg/kg MAD readout and into 2H 2027 – ","length":145,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, May 12, 2026--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended March 31, 2026, and recent corporate highlights.","length":395,"tagName":"p"},{"type":"text","content":""We made encouraging progress during the first quarter of 2026 in our FREEDOM2-DM1 trial. The 5 mg/kg cohort — the initial dose cohort — demonstrated a favorable tolerability profile and promising efficacy trends, reinforcing our confidence in PGN-EDODM1's potential at higher doses," said James McArthur, PhD, Preside...